Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited Share · INE915B01019 (XBOM) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak

Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Ind-Swift Laboratories Limited
No Price
Closing Price XBOM 30.04.2026: 138,30 INR
30.04.2026 10:00
Current Prices from Ind-Swift Laboratories Limited
ExchangeTickerCurrencyLast TradePriceDaily Change
XNSE: NSE
NSE
INDSWFTLAB.NS
INR
30.04.2026 10:00
138,00 INR
-
XBOM: MSE
MSE
INDSWFTLAB.BO
INR
30.04.2026 09:59
138,30 INR
-
Share Float & Liquidity
Free Float 43,05 %
Shares Float 37,33 M
Shares Outstanding 86,71 M
Company Profile for Ind-Swift Laboratories Limited Share
Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, alcohol abstinence, and antineoplastic, as well as various products for ADHD symptoms. It provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, Clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. The company also offers early and late phase drug development, process research and development, contract and API manufacturing, and custom chemicals and synthesis; and analytical development, regulatory support, chemistry, impurity profiling, isolation, discovery, identification and characterization, and project management services. It also exports its products. Ind-Swift Laboratories Limited was founded in 1995 and is based in Manimajra, India.

Company Data

Name Ind-Swift Laboratories Limited
Company Ind-Swift Laboratories Limited
Website https://www.indswiftlabs.com
Primary Exchange XBOM MSE
ISIN INE915B01019
Asset Class Share
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Navrattan R. Munjal
Market Capitalization 12 Mrd.
Country India
Currency INR
Employees 0,0 T
Address Shivalik Enclave, 160101 Manimajra
IPO Date 2002-07-01

Ticker Symbols

Name Symbol
MSE INDSWFTLAB.BO
NSE INDSWFTLAB.NS
More Shares
Investors who hold Ind-Swift Laboratories Limited also have the following shares in their portfolio:
BHP BILLITON FIN.12/24MTN
BHP BILLITON FIN.12/24MTN Bond
SEADRILL 2021 LTD
SEADRILL 2021 LTD Share